⌘+K

Pulse Explore Communities Researchers Journals

Home Communities Explore

April 9, 2024Neurology

Safety and Tolerability of Ecopipam in Tourette Syndrome with Psychiatric Comorbidities (P10-3.001)

Donald L. Gilbert Timothy Cunniff Frederick Munschauer George B. Karkanias Sarah Atkinson Stephen Wanaski

View at Publisher

Ask AI

Bookmark

Share

Abstract

To evaluate the effect of ecopipam in treating children and adolescents with Tourette Syndrome (TS) on measures of attention-deficit hyperactivity disorder (ADHD), anxiety disorders (ANX), obsessive-compulsive disorder (OCD) and depression.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Gilbert et al. (2024) studied this question.

synapsesocial.com/papers/68e6fdb8b6db643587678169 https://doi.org/10.1212/wnl.0000000000204698

View at Publisher

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Efficacy and Safety of Ecopipam for Tourette Syndrome: Results from a Phase 3, Double-blind, Placebo-controlled, Randomized Withdrawal Trial (PL5.004)RCT · 2026
2Efficacy and Safety of Ecopipam for Tourette SyndromeRCT · 2026 · 4 citations
3Efficacy and safety of ecopipam for Tourette syndrome: An updated systematic review and meta-analysis of randomized controlled trialsMeta-Analysis · 2026
4Efficacy and Safety of Ecopipam in Treatment of Tourette Syndrome: A Systematic Review and Meta-analysis with GRADE Assessment (P2-16.008)Human Clinical Trial · 2026
5Effect of Ecopipam, a Selective Dopamine-1 Receptor Antagonist, on Tic Characteristics as Assessed by the YGTSS: Results from the Phase IIb (D1AMOND) Randomized, Double-blind, Placebo-controlled Clinical Trial in Tourette Syndrome (S30.009)2024 · 1 citations

More related papers

Exposure-response (ER) and Clinical Trial Simulations for Efficacy of Ecopipam in Adults and Pediatrics with Tourette’s Syndrome (TS) (P2-16.001)2026
Receptor Selectivity Profile and Clinical Significance of Ecopipam and Relevant Metabolites: A Potential New Treatment for Tourette Syndrome (TS) (P2-16.002)2026
Plain Language Summary of a Phase 2b Randomized Controlled Trial of Ecopipam and Its 12-Month Open-Label Extension in Children and Adolescents With Tourette Syndrome2026

More from Neurology

Role of APOE ɛ4 and ɛ2 With Longitudinal Cognitive Decline Among Those With Exceptional LongevityFri,
Associations of Antibodies Against Several Infections With Alzheimer Disease NeuropathologyFri,